We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Butterfly-Inspired Imaging Sensor Accurately Detects Cancer Cells

By LabMedica International staff writers
Posted on 06 Nov 2023

Ultraviolet (UV) light is a type of electromagnetic radiation that has a shorter wavelength than visible light but longer than X-rays. More...

It is divided into three categories: UVA, UVB, and UVC, each with its unique range of wavelengths. Detecting UV light is complex since it's invisible to the human eye, which makes it difficult to distinguish between these categories. In contrast, butterflies have the capability to see the slight variances in the UV spectrum in the same way humans perceive different colors such as blues and greens. This ability of the Papilio xuthus butterfly has now inspired researchers to create a sensor that can detect UV light which is otherwise undetectable by human eyes.

At the University of Illinois Urbana-Champaign (Urbana, IL, USA), scientists have engineered a sensor that includes layers of photodiodes and utilizes perovskite nanocrystals (PNCs) to image the UV spectrum. PNCs are semiconductor nanocrystals with distinct features that are adaptable based on their size and composition, much like quantum dots, which changes their absorbance and emission traits. These have become promising materials for various sensor-based applications including in solar cells and LED technology. PNCs are notably effective in identifying UV and wavelengths lower than what traditional silicon detectors can handle. In this new sensor, the PNC layer captures UV photons and converts them into visible light (in the green spectrum), which is then recorded by the underlying silicon photodiodes. By processing these readings, the sensor can map and identify UV signatures with precision.

Cancerous tissues often contain higher levels of certain biomedical markers such as amino acids, proteins, and enzymes compared to healthy tissues. When stimulated by UV light, these substances emit a fluorescence in the UV and visible spectrums—a phenomenon known as autofluorescence. This difference in fluorescence between cancerous and healthy cells, due to varying concentrations of these markers, allows them to be distinguished from one another. The researchers tested their imaging technology on its ability to differentiate markers associated with cancer, and it proved to distinguish between cancerous and non-cancerous cells with a 99% level of certainty. The developers of this sensor anticipate its use in surgical settings, assisting surgeons in determining the extent of tissue removal needed to achieve cancer-free margins, thereby supporting the surgical decision-making process in tumor removal.

“Imaging in the UV region has been limited and I would say that has been the biggest roadblock for making scientific progress,” said bioengineering professor Shuming Nie who led the research. “Now we have come up with this technology where we can image UV light with high sensitivity and can also distinguish small wavelength differences. This new imaging technology is enabling us to differentiate cancerous versus healthy cells and is opening up new and exciting applications beyond just health.”

Related Links:
University of Illinois Urbana-Champaign


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.